https://www.vumedi.com/video/year-in-review-2024-key-clinical-trials-in-prostate-cancer/, 视频播放量 6、弹幕量 0、点赞数 0、投硬币枚数 0、收藏人数 0、转发人数 0, 视频作者 enjoy_cc, 作者简介 ,相关视频:
Returning from ASCO 2024, Sandy Srinivas, MD, discusses the results from the PSMAfore trial, which compared lutetium-177(177Lu)-PSMA-617 with alternate androgen receptor pathway inhibitors [ARPIs] in patients with metastatic castration-resistant prostate cancer. The trial showed that177Lu-PSMA-617 ...
PROSTATE cancer patientsThe article discusses a study on the projected increase in prostate cancer cases globally by 2040, with diagnoses expected to more than double due to factors such as improved life expectancy and an aging population.Harris, Emily...
Prostate cancer is a major disease that threatens men’s health. Its rapid progression, easy metastasis, and late castration resistance have brought obstacles to treatment. It is necessary to find new effective anticancer methods. Ferroptosis is a novel
Patient-reported quality of life was captured using The Expanded Prostate Cancer Index Composite (EPIC) survey. The questionnaire was administered at baseline and at one month follow-up. Results were analyzed using descriptive statistics. All patients completed treatment as planned and had minimum ...
ArticleOpen access22 May 2024 Introduction Many decades of research have established the fundamental understanding of cancer as an anarchistic proliferation and dissemination of cells caused by acquired mutations in key driver genes1. During the past decade, the most common cancer types have been exten...
WebMD's slideshow covers prostate cancer: who's at risk, symptoms, tests, staging, treatments, survival, and foods that may help lower your risk for prostate cancer.
High-risk prostate cancer (PCa) harbours a risk of local, regional and systemic relapse requiring the combination of a loco-regional treatment such as external beam radiotherapy for controlling the pelvic-confined disease, combined with an androgen deprivation therapy (ADT) to potentiate irradiation ...
A single-arm, phase I/II clinical trial in China enrolled 12 oligometastatic prostate cancer patients. All patients received neoadjuvant endocrine therapy and neoadjuvant local radiotherapy after 1 month, followed by robot-assisted radical prostatectomy for all patients. The results showed that the avera...
According to the American Cancer Society, prostate cancer is the second most common cause of cancer-related mortality for US men. A continuing research challenge is to improve diagnosis (especially the ability to detect uncommon aggressive cancers) and i